Published Online: February 20, 2014. doi:10.1001/jama.2014.850.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Shoulson reported serving as a consultant regarding experimental therapeutics for Alkermes, AstraZeneca, Auspex Pharmaceuticals, AZTherapies, Caravel Group, Chelsea Therapeutics, Edison Pharmaceuticals, Impax, Ipsen, Isis, Johnson & Johnson, Knopp Biosciences, Link Medicine Lundbeck, Genzyme, Innovation Consulting Group, Medtronic, Neuroglobe Ltd, Omeros Corporation, Orphazyme, Pick Research Solutions, Prana Biotechnology, Salamandra LLC, Seneb Biosciences, Shire HRT, Sofinnova Venture Partners, Velocity Pharmaceuticals Voyager, and Third Rock Ventures; serving as a consultant for the University of California at Irvine, University of Rochester, Columbia University, the Parkinson’s Disease Foundation, and the Micheal J. Fox Foundation; serving on the oversight committee for National Institute of Neurological Disorders and Stroke (NeuroNext); and serving on a Randomized Clinical Trial Steering Committee for Partners (Massachusetts General Hospital) Care. Dr Shoulson is also associate editor, JAMA Neurology. No other authors reported disclosures.
Funding/Support: This research was supported by the Georgetown University Center of Excellence in Regulatory Science and Innovation, a cooperative agreement (FD U01004319) funded by the US Food and Drug Administration (FDA).
Role of the Sponsors: The FDA had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation or approval of the manuscript; or the decision to submit the manuscript for publication. The FDA reviewed the manuscript without comment prior to submission.
Disclaimer: The opinions expressed in this Viewpoint are those of the authors and do not represent the position or opinion of the FDA.